Polyglutamation of antifolates is not required for induction of extracellular release of adenosine or expression of their anti-inflammatory effects.

@article{Urakawa2000PolyglutamationOA,
  title={Polyglutamation of antifolates is not required for induction of extracellular release of adenosine or expression of their anti-inflammatory effects.},
  author={Kazumi Urakawa and Masahiko Mihara and Tadaki Suzuki and Akinori Kawamura and Ken‐ichi Akamatsu and Yasuhisa Takeda and Naoyuki Kamatani},
  journal={Immunopharmacology},
  year={2000},
  volume={48 2},
  pages={
          137-44
        }
}
Methotrexate (MTX) exerts an anti-inflammatory effect, reportedly by enhancing the release of adenosine, through an accumulation of 5-amino-4-imidazolecarboxamide ribonucleotide (AICAR). To examine the role of polyglutamation in promoting anti-inflammatory effects by antifolates, we tested whether a new antifolate designed to be resistant to intracellular polyglutamation (MX-68) exhibited anti-inflammatory effects and stimulated adenosine release. Both MX-68 and MTX (at concentrations greater… Expand
Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68.
TLDR
Findings confirm that adenosine, acting at A(2A) and A(3) receptors, is a potent regulator of inflammation. Expand
Low-Dose Methotrexate Results in the Selective Accumulation of Aminoimidazole Carboxamide Ribotide in an Erythroblastoid Cell Line
TLDR
Characterizing the range of MTX concentrations that selectively promote ZMP accumulation while preserving pyrimidine biosynthesis may lead to optimization of low-dose MTX therapy. Expand
Low-Dose Methotrexate Results in the Selective Accumulation of Aminoimidazole Carboxamide Ribotide in an Erythroblastoid Cell Line s
Therapeutic and toxic response to low-dose methotrexate (MTX) in the treatment of autoimmune disease continues to be highly variable, resulting in a critical need to identify predictive biomarkers ofExpand
Nonclassical Antifolate Compounds as Dihydrofolate Reductase Inhibitors: Synthesis and Biological Evaluation
Dihydrofolate reductase (DHFR) catalyzes the reduction of folate or dihydrofolate into tetrahydrofolate, which then converted into N, N-methylenetetrahydrofolate. This later compound functions as theExpand
Combination of MTX and LEF attenuates inflammatory bone erosion by down-regulation of receptor activator of NF-kB ligand and interleukin-17 in type II collagen-induced arthritis rats
TLDR
Combination therapy would relive the synovium hypertrophy through depressing cell viability and osteoclasia through decreasing RANKL and increasing OPG expression and combination was superior to monotherapy. Expand
Nimesulide improves the disease modifying anti-rheumatic profile of methotrexate in mice with collagen-induced arthritis.
TLDR
Nimesulide significantly improved the disease modifying anti-rheumatic profile of methotrexate in terms of arthritic index and joint mobility and failed to show any radiological evidence of articular protection, but significantly improved metotrexate-induced joint protection as judged by X-ray analysis. Expand
Nimesulide Improves the Symptomatic and Disease Modifying Effects of Leflunomide in Collagen Induced Arthritis
TLDR
Combination of nimesulide and leflunomide significantly improved symptomatic and arthritic disease progression (radiological, pathological and Myeloperoxidase enzyme activity) in collagen induced arthritis animal model. Expand
PHOTOCHEMICAL ELECTRON TRANSFER REACTIONS OF TALOTREXIN
Abstract Talotrexin is an antifolate drug with promising antitumor activity. The present study deals with the photodegradation of talotrexin. An aqueous solution of talotrexin was irradiated underExpand
AMP kinase signaling determines whether c-Jun N-terminal kinase promotes survival or apoptosis during glucose deprivation.
TLDR
The results demonstrated how AMPK controls the molecular mechanism underlying the differential biological functions of JNK, and they also provided a novel explanation for the antiapoptotic role of LKB1. Expand
The Therapeutic Targeting Of Folate Receptor Alpha Positive Tumors Via Folate Receptor Selective Novel 5- And 6- Substituted Pyrrolo [2,3-D]pyrimidine Antifolates"
THE THERAPEUTIC TARGETING OF FOLATE RECPTOR ALPHA POSITIVE TUMORS VIA FOLATE RECEPTOR-SELECTIVE NOVEL 5-AND 6SUBSTITUTED PYRROLO [2,3-D] PYRIMIDINE ANTIFOLATES
...
1
2
...

References

SHOWING 1-10 OF 24 REFERENCES
In vitro and in vivo biological activities of a novel nonpolyglutamable anti-folate, MX-68.
TLDR
Polyglutamation is not always a prerequisite in the anti-rheumatic effects of anti-folate, and since intracellular accumulation of polyglutamates is thought to have adverse effects, MX-68 may become a more potent and less toxic anti- rheumatic drug than MTX. Expand
The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites.
TLDR
Evidence is provided that sulfasalazine and methotrexate may be described as a newly recognized family of anti-inflammatory agents that share the property of using adenosine as an antagonist of inflammation. Expand
A novel antifolate, MX-68, inhibits the development of autoimmune disease in MRL/lpr mice.
TLDR
It is concluded that MX-68 is beneficial for the treatment of autoimmune kidney disease in mice and may be useful for other related diseases such as systemic lupus erythematosus. Expand
The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation.
TLDR
Results indicate that methotrexate is a nonsteroidal antiinflammatory agent, the antiphlogistic action of which is due to increased adenosine release at inflamed sites. Expand
Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates.
TLDR
The enhanced inhibitory potency of methotrexate (MTX) polyglutamates and dihydrofolate pentaglutamate on the catalytic activity of AICAR transformylase purified from MCF-7 human breast cancer cells is reported and a model depicting these complex interactions is postulated. Expand
Preventive effect of a novel antifolate, MX-68, in murine systemic lupus erythematosus (SLE).
TLDR
The preventive effects of a novel nonpolyglutamatable antifolate, MX-68, on two experimental murine models of systemic lupus erythematosus (SLE) and chronic graft-versus-host disease (GVHD) mice suggest that MX- 68 might be a more useful drug for the treatment of SLE. Expand
Inhibition of leukotriene B4 synthesis in neutrophils from patients with rheumatoid arthritis by a single oral dose of methotrexate.
TLDR
The absence of a significant change in either 3H-labeled arachidonic acid release or platelet-activating factor generation indicates that the observed decrease in LTB4 synthesis was apparently not caused by diminished phospholipase A2 activity, and inhibition of 5-lipoxygenase activity and possible suppression of leukotriene A4 epoxide hydrolase activity. Expand
Urinary adenosine and aminoimidazolecarboxamide excretion in methotrexate-treated patients with psoriasis.
TLDR
Methotrexate treatment of patients with psoriasis inhibits AICA ribotide transformylase and adenosine metabolism, which may be partially responsible for the immunosuppressive effect. Expand
A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis.
TLDR
5,10-Dideazatetrahydrofolate was found to deplete cellular ATP and GTP over the same concentrations as those inhibitory to leukemic cell growth, suggesting that the locus of DDATHF action was in the de novo purine biosynthesis pathway. Expand
Formation and retention and biological activity of N10-propargyl-5,8-dideazafolic acid (CB3717) polyglutamates in L1210 cells in vitro.
TLDR
It is shown that CB3717 can undergo polyglutamation in tumour cells and that the metabolites are preferentially retained giving rise to prolonged TS inhibition, by virtue of their potent TS inhibitory activity. Expand
...
1
2
3
...